Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01535924 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 1 study, sponsored by Beth Christian.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01535924 is a Phase 1 study that has completed, run by Beth Christian. The registered enrollment target is 26 participants.
The verdict
NCT01535924, a Phase 1 study, has completed, sponsored by Beth Christian.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of bendamustine hydrochloride when given together with gemcitabine hydrochloride and to see how well it works in treating patients with relapsed or refractory Hodgkin lymphoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride and bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug, combination chemotherapy, may kill more cancer cells.
Interventions
- DRUG bendamustine hydrochloride
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-02-09 |
| Est. Completion | 2019-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01535924
The ClinicalTrials.gov registry entry for NCT01535924 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Christian, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bendamustine hydrochloride is the first listed.
NCT01535924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01535924 about?
NCT01535924 is a clinical study titled "Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma". This phase I/II trial studies the side effects and best dose of bendamustine hydrochloride when given together with gemcitabine hydrochloride and to see how well it works in treating patients with relapsed or refractory Hodgkin lymphoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride ...
What is the current status of trial NCT01535924?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-02-09. Estimated completion is 2019-02-20.
What interventions are being tested in trial NCT01535924?
The interventions under investigation include: bendamustine hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01535924?
This trial is sponsored by Beth Christian, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.